Share on StockTwits

ACADIA Pharmaceuticals (NASDAQ:ACAD) CEO Uli Hacksell unloaded 15,000 shares of the company’s stock on the open market in a transaction dated Friday, August 15th. The stock was sold at an average price of $22.89, for a total value of $343,350.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) traded down 1.35% during mid-day trading on Friday, hitting $22.59. The stock had a trading volume of 974,585 shares. ACADIA Pharmaceuticals has a 1-year low of $15.64 and a 1-year high of $32.00. The stock’s 50-day moving average is $21.43 and its 200-day moving average is $22.53. The company’s market cap is $2.246 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.22) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.17) by $0.05. Analysts expect that ACADIA Pharmaceuticals will post $-0.85 EPS for the current fiscal year.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.

Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.